Serial Endoscopic Evaluation of Esophageal Disease in a Cancer Model: A Paradigm Shift for Esophageal Adenocarcinoma (EAC) Drug Discovery and Development

References

• Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893–917.
   PubMed Web of Science ®Google Scholar
• Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62(1):10–29.
   PubMed Web of Science ®Google Scholar
• Thrift AP. The epidemic of oesophageal carcinoma: where are we now? Cancer Epidemiol. 2016;41:88–95.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin. 2017;67(1):7–30.
   PubMed Web of Science ®Google Scholar
• Njei B, McCarty TR, Birk JW. Trends in esophageal cancer survival in United States adults from 1973 to 2009: a SEER database analysis. J Gastroenterol Hepatol. 2016;31(6):1141–6.
   PubMed Web of Science ®Google Scholar
• Reid BJ, Li X, Galipeau PC, Vaughan TL. Barrett's oesophagus and oesophageal adenocarcinoma: time for a new synthesis. Nat Rev Cancer. 2010;10(2):87–101.
   PubMed Web of Science ®Google Scholar
• Engel LS, Chow WH, Vaughan TL, Gammon MD, Risch HA, Stanford JL, et al. Population attributable risks of esophageal and gastric cancers. J Natl Cancer Inst. 2003;95(18):1404–13.
   PubMed Web of Science ®Google Scholar
• Lagergren J, Bergstrom R, Adami HO, Nyren O. Association between medications that relax the lower esophageal sphincter and risk for esophageal adenocarcinoma. Ann Intern Med. 2000;133(3):165–75.
   PubMed Web of Science ®Google Scholar
• Islami F, Kamangar F. Helicobacter pylori and esophageal cancer risk: a meta-analysis. Cancer Prev Res (Phila). 2008;1(5):329–38.
   PubMed Web of Science ®Google Scholar
• Poynton AR, Walsh TN, O'Sullivan G, Hennessy TP. Carcinoma arising in familial Barrett's esophagus. Am J Gastroenterol. 1996;91(9):1855–6.
   PubMed Web of Science ®Google Scholar
• Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med. 1999;340(11):825–31.
   PubMed Web of Science ®Google Scholar
• Anderson LA, Watson RG, Murphy SJ, Johnston BT, Comber H, Mc Guigan J, et al. Risk factors for Barrett's oesophagus and oesophageal adenocarcinoma: results from the FINBAR study. World J Gastroenterol. 2007;13(10):1585–94.
   PubMed Web of Science ®Google Scholar
• Oh DS, DeMeester SR, Dunst CM, Mori R, Lehman BJ, Kuramochi H, et al. Validation of a rodent model of Barrett's esophagus using quantitative gene expression profiling. Surg Endosc. 2009;23(6):1346–52.
   PubMed Web of Science ®Google Scholar
• Macke RA, Nason KS, Mukaisho K, Hattori T, Fujimura T, Sasaki S, et al. Barrett's esophagus and animal models. Ann N Y Acad Sci. 2011;1232: 392–400.
   PubMed Web of Science ®Google Scholar
• Buskens CJ, Hulscher JB, van Gulik TM, Ten Kate FJ, van Lanschot JJ. Histopathologic evaluation of an animal model for Barrett's esophagus and adenocarcinoma of the distal esophagus. J Surg Res. 2006;135(2):337–44.
   PubMed Web of Science ®Google Scholar
• Chen X, Yang G, Ding WY, Bondoc F, Curtis SK, Yang CS. An esophagogastroduodenal anastomosis model for esophageal adenocarcinogenesis in rats and enhancement by iron overload. Carcinogenesis. 1999;20(9):1801–8.
   PubMed Web of Science ®Google Scholar
• Li Y, Martin RC, 2nd. Reflux injury of esophageal mucosa: experimental studies in animal models of esophagitis, Barrett's esophagus and esophageal adenocarcinoma. Dis Esophagus. 2007;20(5):372–8.
   PubMed Web of Science ®Google Scholar
• Miwa K, Sahara H, Segawa M, Kinami S, Sato T, Miyazaki I, et al. Reflux of duodenal or gastro-duodenal contents induces esophageal carcinoma in rats. Int J Cancer. 1996;67(2):269–74.
   PubMed Web of Science ®Google Scholar
• Xu X, LoCicero J, 3rd, Macri E, Loda M, Ellis FH, Jr. Barrett's esophagus and associated adenocarcinoma in a mouse surgical model. J Surg Res. 2000;88(2):120–4.
   PubMed Web of Science ®Google Scholar
• Yamashita Y, Homma K, Kako N, Clark GW, Smyrk TC, Hinder RA, et al. Effect of duodenal components of the refluxate on development of esophageal neoplasia in rats. J Gastrointest Surg. 1998;2(4):350–5.
   PubMedGoogle Scholar
• Buttar NS, Wang KK, Leontovich O, Westcott JY, Pacifico RJ, Anderson MA, et al. Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett's esophagus. Gastroenterology. 2002;122(4):1101–12.
   PubMed Web of Science ®Google Scholar
• Gibson MK, Zaidi AH, Davison JM, Sanz AF, Hough B, Komatsu Y, et al. Prevention of Barrett esophagus and esophageal adenocarcinoma by smoothened inhibitor in a rat model of gastroesophageal reflux disease. Ann Surg. 2013;258(1):82–8.
   PubMed Web of Science ®Google Scholar
• Schiffman SC, Li Y, Dryden G, Li X, Martin RC. Positive correlation of image analysis by mini-endoscopy with micro-PET scan and histology in rats after esophagoduodenal anastomosis. Surg Endosc. 2010;24(11):2835–41.
   PubMed Web of Science ®Google Scholar
• Budde MD, Gold E, Jordan EK, Frank JA. Differential microstructure and physiology of brain and bone metastases in a rat breast cancer model by diffusion and dynamic contrast enhanced MRI. Clin Exp Metastasis. 2012;29(1):51–62.
   PubMed Web of Science ®Google Scholar
• Petre C, Ni Y, Marchal G, Yu J, Wevers M, Lauffer RB, et al. Detection and characterization of primary liver cancer in rats by MS-264-enhanced MRI. Magn Reson Med. 1996;35(4):532–9.
   PubMed Web of Science ®Google Scholar
• Yamaguchi M, Mitsuda M, Ezawa K, Nakagami R, Furuta T, Sekine N, et al. Artifact-reduced simultaneous MRI of multiple rats with liver cancer using PROPELLER. J Magn Reson Imaging. 2013;38(1):225–30.
   PubMed Web of Science ®Google Scholar
• Kosovec JE, Zaidi AH, Komatsu Y, Cothron K, Sato T, Thompson DV, et al. Establishing magnetic resonance imaging as an accurate and reliable tool to diagnose and monitor esophageal cancer in a rat model. PLoS One. 2014;9(4):e93694.
   PubMed Web of Science ®Google Scholar
• Lu S, Lowe AW, Triadafilopoulos G, Hsiung PL, Hao Y, Crawford JM, et al. Endoscopic evaluation of esophago-gastro-jejunostomy in rat model of Barrett's esophagus. Dis Esophagus. 2009;22(4):323–30.
   PubMed Web of Science ®Google Scholar
• Greenawalt DM, Duong C, Smyth GK, Ciavarella ML, Thompson NJ, Tiang T, et al. Gene expression profiling of esophageal cancer: comparative analysis of Barrett's esophagus, adenocarcinoma, and squamous cell carcinoma. Int J Cancer. 2007;120(9):1914–21.
   PubMed Web of Science ®Google Scholar
• Cheng P, Gong J, Wang T, Chen J, Liu GS, Zhang R. Gene expression in rats with Barrett's esophagus and esophageal adenocarcinoma induced by gastroduodenoesophageal reflux. World J Gastroenterol. 2005;11(33):5117–22.
   PubMed Web of Science ®Google Scholar
• Hao Y, Triadafilopoulos G, Sahbaie P, Young HS, Omary MB, Lowe AW. Gene expression profiling reveals stromal genes expressed in common between Barrett's esophagus and adenocarcinoma. Gastroenterology. 2006;131(3):925–33.
   PubMed Web of Science ®Google Scholar
• Rabinovitch PS, Longton G, Blount PL, Levine DS, Reid BJ. Predictors of progression in Barrett's esophagus III: baseline flow cytometric variables. Am J Gastroenterol. 2001;96(11):3071–83.
   PubMed Web of Science ®Google Scholar
• Morales CP, Souza RF, Spechler SJ. Hallmarks of cancer progression in Barrett's oesophagus. Lancet. 2002;360(9345):1587–9.
   PubMed Web of Science ®Google Scholar
• Sikkema M, Kerkhof M, Steyerberg EW, Kusters JG, van Strien PM, Looman CW, et al. Aneuploidy and overexpression of Ki67 and p53 as markers for neoplastic progression in Barrett's esophagus: a case-control study. Am J Gastroenterol. 2009;104(11):2673–80.
   PubMed Web of Science ®Google Scholar
• Kosovec JE, Zaidi AH, Kelly LA, Rotoloni CL, Vytlacil C, DiCarlo C, et al. Preclinical study of AUY922, a novel Hsp90 inhibitor, in the treatment of esophageal adenocarcinoma. Ann Surg. 2016;264(2):297–304.
   PubMed Web of Science ®Google Scholar
• Zaidi AH, Kosovec JE, Matsui D, Omstead AN, Raj M, Rao RR, et al. PI3K/mTOR Dual Inhibitor, LY3023414, Demonstrates Potent Antitumor Efficacy Against Esophageal Adenocarcinoma in a Rat Model. Ann Surg. 2017;226(1):91–98
   Google Scholar
• Curvers WL, Kate FJ, Krishnadath KK, Visser M, Elzer B, Baak LC, et al. Low-grade dysplasia in Barrett's esophagus: overdiagnosed and underestimated. Am J Gastroenterol. 2010;105:1523–1530; doi:10.1038/ajg.2010.171;
   PubMed Web of Science ®Google Scholar
• Malhotra U, Zaidi AH, Kosovec JE, Kasi PM, Komatsu Y, Rotoloni CL, et al. Prognostic value and targeted inhibition of survivin expression in esophageal adenocarcinoma and cancer-adjacent squamous epithelium. PLoS One. 2013;8(11):e78343.
   PubMed Web of Science ®Google Scholar